Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib continuation with second-line endocrine therapy in HR-positive/HER2-negative advanced breast cancer
2017-002781-48Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib, fulvestrant and letrozole in breast cancer (2 arms), sponsored by MEDSIR. Primary endpoint: Progression-free survival. Started Jan 2019; status: completed.
02
Drugs
palbociclibfulvestrantletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-002781-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002781-48.